AQR Capital Management LLC Has $5.20 Million Stake in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• AQR Capital Management has increased its stake in Xeris Biopharma by 13.4%, owning approximately 0.61% of the company, which is valued at about $5.20 million.
• Xeris Biopharma's stock has experienced a drop of 2.5%, currently priced at $7.49, with a market cap of $1.21 billion.
• Despite recent insider sales, analysts maintain a Moderate Buy rating on Xeris Biopharma, with a consensus price target of $7.08.

AQR Capital Management LLC boosted its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 13.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 946,766 shares of the company's stock after buying an additional 111,826 shares during the quarter. AQR Capital Management LLC owned approximately 0.61% of Xeris Biopharma worth $5,198,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of XERS. Nuveen LLC acquired a new stake in Xeris Biopharma in the 1st quarter valued at $12,240,000. Invesco Ltd. boosted its stake in Xeris Biopharma by 1,387.8% in the 1st quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock valued at $5,637,000 after buying an additional 957,822 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in Xeris Biopharma by 137.6% in the 1st quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock valued at $7,749,000 after buying an additional 817,525 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Xeris Biopharma in the 1st quarter valued at $4,456,000. Finally, Informed Momentum Co LLC boosted its stake in Xeris Biopharma by 320.3% in the 1st quarter. Informed Momentum Co LLC now owns 934,646 shares of the company's stock valued at $5,131,000 after buying an additional 712,269 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Stock Down 2.5%

XERS stock opened at $7.49 on Friday. The company has a market cap of $1.21 billion, a P/E ratio of -35.66 and a beta of 0.13. Xeris Biopharma Holdings, Inc. has a twelve month low of $2.69 and a twelve month high of $8.03. The business has a fifty day moving average of $6.49 and a 200-day moving average of $5.27.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. As a group, equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other news, Director Marla Persky sold 15,500 shares of the business's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $7.72, for a total transaction of $119,660.00. Following the completion of the sale, the director owned 142,000 shares in the company, valued at $1,096,240. The trade was a 9.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey W. Sherman sold 42,232 shares of the business's stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $7.92, for a total value of $334,477.44. Following the sale, the director owned 219,188 shares of the company's stock, valued at approximately $1,735,968.96. The trade was a 16.15% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 207,732 shares of company stock worth $1,550,437. Insiders own 6.47% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on XERS shares. Leerink Partners lifted their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a research report on Tuesday, August 19th. Wall Street Zen downgraded Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Finally, HC Wainwright started coverage on Xeris Biopharma in a research report on Tuesday, August 12th. They issued a "buy" rating and a $10.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $7.08.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.